In Autumn 2020, DOAJ will be relaunching with a new website with updated functionality, improved search, and a simplified application form. More information is available on our blog. Our API is also changing.

Hide this message

Expression of enterovirus 71 capsid protein VP1 in Escherichia coli and its clinical application

Brazilian Journal of Microbiology. 2013;44(4):1215-1222

 

Journal Homepage

Journal Title: Brazilian Journal of Microbiology

ISSN: 1517-8382 (Print); 1678-4405 (Online)

Publisher: Sociedade Brasileira de Microbiologia

LCC Subject Category: Science: Microbiology

Country of publisher: Brazil

Language of fulltext: English

Full-text formats available: PDF, HTML, XML

 

AUTHORS


Mei Shi (Suzhou University)

Yaping Zhou (Changzhou 21st Biotech Research Institute)

Limin Cao (Changzhou 21st Biotech Research Institute)

Cuijun Ding (Changzhou Children's Hospital)

Yun Ji (Suzhou University)

Qinbo Jiang (Suzhou University)

Xiping Liu (Suzhou University)

Xiang Li (Suzhou University)

Xueling Hou (Suzhou University)

Hongjun Peng (Suzhou University)

Weifeng Shi (Suzhou University)

EDITORIAL INFORMATION

Peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 39 weeks

 

Abstract | Full Text

The VPl gene of enterovirus 71 (EV71) was synthesized, construct a recombinant plasmid pET15b/VP1 and expressed in E. coli BL21. The recombinant VP1 protein could specifically react with EV71-infected patient sera without the cross-reaction with serum antibodies of coxsackievirus A16 (CA16), A4, A5, B3 and B5 as well as echovirus 6. In acute and convalescent phases, IgM and IgG antibodies of 182 serum samples were detected by ELISA with recombinant VP1 protein as a coated antigen. The results showed that the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of IgM antibodies in serum samples for the diagnosis of EV71 infection were 90.1, 98.4, 98.8 and 88.7%, respectively; similarly, those of IgG antibodies in serum samples were 82.4, 89.1, 91.5 and 78.1%, respectively. Five of 80 samples (6.25%) from CA16infected patients were detected positive by ELISA with recombinant VP1 protein in which indicated the cross reactions and 0 of 5 samples from patients infected with other enteroviruses including CA4, CA5, CB3, CB5 and echovirus 6. Therefore, the recombinant VP1 protein of EV7l may provide a theoretical reference for establishing an effective antibody screening of IgM for EV71-infected patients with clinically suspected hand, foot, and mouth disease (HFMD).